These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 20023240)

  • 21. Reversal of doxorubicin resistance in multidrug resistant melanoma cells in vitro and in vivo by dipyridamole.
    Desai PB; Duan J; Sridhar R; Damle BD
    Methods Find Exp Clin Pharmacol; 1997 May; 19(4):231-9. PubMed ID: 9228648
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Simultaneous delivery of doxorubicin and GG918 (Elacridar) by new polymer-lipid hybrid nanoparticles (PLN) for enhanced treatment of multidrug-resistant breast cancer.
    Wong HL; Bendayan R; Rauth AM; Wu XY
    J Control Release; 2006 Dec; 116(3):275-84. PubMed ID: 17097178
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Novel phosphonium salts display in vitro and in vivo cytotoxic activity against human ovarian cancer cell lines.
    Manetta A; Gamboa G; Nasseri A; Podnos YD; Emma D; Dorion G; Rawlings L; Carpenter PM; Bustamante A; Patel J; Rideout D
    Gynecol Oncol; 1996 Feb; 60(2):203-12. PubMed ID: 8631539
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models.
    Schmid FA; Sirotnak FM; Otter GM; DeGraw JI
    Cancer Treat Rep; 1987; 71(7-8):727-32. PubMed ID: 3607784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines.
    Kars MD; Işeri OD; Gunduz U; Molnar J
    Chemotherapy; 2008; 54(3):194-200. PubMed ID: 18560226
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.
    Goren D; Horowitz AT; Tzemach D; Tarshish M; Zalipsky S; Gabizon A
    Clin Cancer Res; 2000 May; 6(5):1949-57. PubMed ID: 10815920
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An ortho-carbonyl substituted hydroquinone derivative is an anticancer agent that acts by inhibiting mitochondrial bioenergetics and by inducing G₂/M-phase arrest in mammary adenocarcinoma TA3.
    Urra FA; Martínez-Cifuentes M; Pavani M; Lapier M; Jaña-Prado F; Parra E; Maya JD; Pessoa-Mahana H; Ferreira J; Araya-Maturana R
    Toxicol Appl Pharmacol; 2013 Mar; 267(3):218-27. PubMed ID: 23333614
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversal of P-gp mediated multidrug resistance in-vitro and in-vivo by FG020318.
    Chen LM; Liang YJ; Ruan JW; Ding Y; Wang XW; Shi Z; Gu LQ; Yang XP; Fu LW
    J Pharm Pharmacol; 2004 Aug; 56(8):1061-6. PubMed ID: 15285852
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effects of suramin in combination with cisplatin on growth and metastasis of lung adenocarcinoma xenografts in mice].
    Zhang P; He JB; Ou LW; Wang XH
    Ai Zheng; 2006 Apr; 25(4):409-13. PubMed ID: 16613671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Nanoparticle-mediated simultaneous and targeted delivery of paclitaxel and tariquidar overcomes tumor drug resistance.
    Patil Y; Sadhukha T; Ma L; Panyam J
    J Control Release; 2009 May; 136(1):21-9. PubMed ID: 19331851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Potent reversal of multidrug resistance by ningalins and its use in drug combinations against human colon carcinoma xenograft in nude mice.
    Chou TC; Guan Y; Soenen DR; Danishefsky SJ; Boger DL
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):379-90. PubMed ID: 15875185
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines.
    Page RL; Hughes CS; Huyan S; Sagris J; Trogdon M
    Anticancer Res; 2000; 20(5B):3533-8. PubMed ID: 11131658
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The nitroxide Tempol modulates anthracycline resistance in breast cancer cells.
    Gariboldi MB; Terni F; Ravizza R; Meschini S; Marra M; Condello M; Arancia G; Monti E
    Free Radic Biol Med; 2006 Apr; 40(8):1409-18. PubMed ID: 16631531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of pO2 on antitumor drug cytotoxicity on MDR and non-MDR variants selected from the LoVo metastatic colon carcinoma cell line.
    Lelong-Rebel I; Brisson C; Fabre M; Bergerat JP; Rebel G
    Anticancer Res; 2008; 28(1A):55-68. PubMed ID: 18383825
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted doxorubicin-containing luteinizing hormone-releasing hormone analogue AN-152 inhibits the growth of doxorubicin-resistant MX-1 human breast cancers.
    Bajo AM; Schally AV; Halmos G; Nagy A
    Clin Cancer Res; 2003 Sep; 9(10 Pt 1):3742-8. PubMed ID: 14506166
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Betamethasone inhibits tumor development, microvessel density and prolongs survival in mice with a multiresistant adenocarcinoma TA3.
    Garrido O; Letelier R; Rosas C; Fuenzalida M; Ferreira A; Lemus D
    Biol Res; 2010; 43(3):317-22. PubMed ID: 21249303
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibitory effect of vanillin-like compounds on respiration and growth of adenocarcinoma TA3 and its multiresistant variant TA3-MTX-R.
    Cordano G; Pezoa J; Muñoz S; Rivera E; Medina J; Núñez-Vergara LJ; Pavani M; Guerrero A; Ferreira J
    Eur J Pharm Sci; 2002 Sep; 16(4-5):255-63. PubMed ID: 12208455
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hepatoma-derived growth factor promotes the resistance to anti-tumor effects of nordihydroguaiaretic acid in colorectal cancer cells.
    Liao F; Liu M; Lv L; Dong W
    Eur J Pharmacol; 2010 Oct; 645(1-3):55-62. PubMed ID: 20674562
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Stilbenes as multidrug resistance modulators and apoptosis inducers in human adenocarcinoma cells.
    Wesolowska O; Wisniewski J; Bielawska-Pohl A; Paprocka M; Duarte N; Ferreira MJ; Dus D; Michalak K
    Anticancer Res; 2010 Nov; 30(11):4587-93. PubMed ID: 21115910
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A fluorescence-based assay for monitoring clinical drug resistance.
    Deniset-Besseau A; Miannay FA; Laplace-Builhé C; Vielh P; Lécart S; Lwaleed BA; Eschwege P; Fontaine-Aupart MP
    J Clin Pathol; 2012 Nov; 65(11):1003-7. PubMed ID: 22859393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.